Integral Diagnostics slams Capitol Health’s ‘opportunistic’ bid
SYDNEY: Integral Diagnostics is urging shareholders to reject the $312 million cash and scrip bid
SYDNEY: Integral Diagnostics is urging shareholders to reject the $312 million cash and scrip bid